Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)
Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –
Halozyme Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Halozyme Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $818.60M, up 49.4% year over year. For fiscal 2025 it was $651.56M, up 36.0% from the year before. The highest annual figure on record is $651.56M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $651.56M | +36.0% |
| FY2024 | Dec 31, 2024 | $479.06M | +23.3% |
| FY2023 | Dec 31, 2023 | $388.57M | +61.8% |
| FY2022 | Dec 31, 2022 | $240.11M | -19.8% |
| FY2021 | Dec 31, 2021 | $299.44M | +440.0% |
| FY2020 | Dec 31, 2020 | $55.45M | – |
| FY2019 | Dec 31, 2019 | -$85.42M | – |
| FY2018 | Dec 31, 2018 | -$49.50M | -136.9% |
| FY2017 | Dec 31, 2017 | $134.05M | – |
| FY2016 | Dec 31, 2016 | -$50.38M | – |
| FY2015 | Dec 31, 2015 | -$37.08M | – |
| FY2014 | Dec 31, 2014 | -$47.52M | – |
| FY2013 | Dec 31, 2013 | -$49.34M | – |
| FY2012 | Dec 31, 2012 | -$64.28M | – |
| FY2011 | Dec 31, 2011 | -$34.30M | – |
| FY2010 | Dec 31, 2010 | -$45.39M | – |
| FY2009 | Dec 31, 2009 | -$40.15M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $240.89M | +141.6% |
| Q1 FY2026 | Mar 31, 2026 | $180.08M | +16.8% |
| Q4 FY2025 | Dec 31, 2025 | $219.03M | +22.7% |
| Q3 FY2025 | Sep 30, 2025 | $178.60M | +54.8% |
| Q2 FY2025 | Jun 30, 2025 | $99.71M | +78.7% |
| Q1 FY2025 | Mar 31, 2025 | $154.22M | +19.2% |
| Q4 FY2024 | Dec 31, 2024 | $178.47M | +74.4% |
| Q3 FY2024 | Sep 30, 2024 | $115.38M | -12.9% |
| Q2 FY2024 | Jun 30, 2024 | $55.79M | -16.5% |
| Q1 FY2024 | Mar 31, 2024 | $129.43M | +48.8% |
| Q4 FY2023 | Dec 31, 2023 | $102.35M | +24.1% |
| Q3 FY2023 | Sep 30, 2023 | $132.41M | +90.2% |
| Q2 FY2023 | Jun 30, 2023 | $66.84M | +66.2% |
| Q1 FY2023 | Mar 31, 2023 | $86.96M | +81.9% |
| Q4 FY2022 | Dec 31, 2022 | $82.45M | -0.1% |
| Q3 FY2022 | Sep 30, 2022 | $69.64M | -42.8% |
| Q2 FY2022 | Jun 30, 2022 | $40.23M | +9.0% |
| Q1 FY2022 | Mar 31, 2022 | $47.80M | -18.0% |
| Q4 FY2021 | Dec 31, 2021 | $82.52M | +62.1% |
| Q3 FY2021 | Sep 30, 2021 | $121.74M | +1901.0% |
| Q2 FY2021 | Jun 30, 2021 | $36.89M | +1019.9% |
| Q1 FY2021 | Mar 31, 2021 | $58.30M | – |
| Q4 FY2020 | Dec 31, 2020 | $50.92M | – |
| Q3 FY2020 | Sep 30, 2020 | $6.08M | – |
| Q2 FY2020 | Jun 30, 2020 | $3.29M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.84M | – |
| Q4 FY2019 | Dec 31, 2019 | -$26.63M | -354.5% |
| Q3 FY2019 | Sep 30, 2019 | -$29.59M | – |
| Q2 FY2019 | Jun 30, 2019 | -$24.79M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.42M | – |
| Q4 FY2018 | Dec 31, 2018 | $10.46M | -93.2% |
| Q3 FY2018 | Sep 30, 2018 | -$18.93M | -193.4% |
| Q2 FY2018 | Jun 30, 2018 | -$18.86M | – |
| Q1 FY2018 | Mar 31, 2018 | -$22.18M | – |
| Q4 FY2017 | Dec 31, 2017 | $153.25M | – |
| Q3 FY2017 | Sep 30, 2017 | $20.26M | – |
| Q2 FY2017 | Jun 30, 2017 | -$17.00M | – |
| Q1 FY2017 | Mar 31, 2017 | -$22.46M | – |
| Q4 FY2016 | Dec 31, 2016 | -$15.77M | – |
| Q3 FY2016 | Sep 30, 2016 | -$8.75M | – |
See a number that looks wrong?